Standard Thiamine Should Be Used in Pediatric Patients
In children with suspected thiamine deficiency, standard thiamine (vitamin B1) should be used rather than benfotiamine, as it is the only form with established pediatric dosing guidelines, FDA approval for deficiency treatment, and proven efficacy in life-threatening conditions.
Rationale Based on Guidelines and FDA Labeling
The ESPGHAN/ESPEN/ESPR/CSPEN pediatric parenteral nutrition guidelines 1 provide specific, evidence-based dosing recommendations for standard thiamine across all pediatric age groups:
- Preterm and term infants (up to 12 months): 0.35-0.50 mg/kg/day
- Children and adolescents (1-18 years): 1.2 mg/day
These recommendations are based on the critical role of thiamine in carbohydrate and lipid metabolism, with requirements directly proportional to carbohydrate intake 1.
The FDA-approved thiamine hydrochloride injection 2 is specifically indicated for:
- Wernicke's encephalopathy
- Infantile beriberi with acute collapse
- Cardiovascular disease due to thiamine deficiency
- Neuritis of pregnancy with severe vomiting
- Prevention of heart failure when administering IV dextrose to thiamine-deficient patients
For acute, life-threatening presentations, the FDA label specifies 25 mg IV cautiously for infantile beriberi with collapse 2.
Clinical Context: Why This Matters
Thiamine deficiency in children presents as medical emergencies requiring immediate intervention:
Life-Threatening Presentations
Recent pediatric case series demonstrate the severity of untreated thiamine deficiency:
Pulmonary hypertensive crisis: Six exclusively breastfed infants (mean age 76 days) presented with severe pulmonary arterial hypertension, hypotensive shock, metabolic acidosis, and severe encephalopathy. Standard thiamine treatment resulted in dramatic improvement in all cases with no major neurological deficits on follow-up 3.
Refractory lactic acidosis: Multiple case reports 4, 5 document severe, life-threatening lactic acidosis in children on parenteral nutrition that resolved within 12 hours of thiamine supplementation. One teenager required ECMO support, with lactate normalizing only after thiamine was administered 4.
High-Risk Pediatric Populations
Children at increased risk include those with 1, 6:
- Prolonged parenteral nutrition without adequate vitamin supplementation
- Heart disease receiving diuretic therapy (15% prevalence of deficiency) 6
- Exclusive breastfeeding from thiamine-deficient mothers 3
- Malabsorption disorders
- Chemotherapy treatment 4
Critical pitfall: Deficiency can develop within days to weeks in parenterally fed children, leading to severe lactic acidosis, Wernicke's encephalopathy, and death 1.
Why Not Benfotiamine in Pediatric Practice?
Benfotiamine is a synthetic thiamine derivative that has gained attention in adult neuropsychiatric research 7. However, it has critical limitations for pediatric use:
No established pediatric dosing guidelines: Neither the ESPGHAN/ESPEN guidelines 1 nor FDA labeling 2 provide pediatric dosing for benfotiamine.
No FDA approval for thiamine deficiency treatment: Benfotiamine lacks regulatory approval for treating acute thiamine deficiency states in any age group.
No pediatric safety or efficacy data: The available literature on benfotiamine focuses on adult neuropsychiatric conditions 7, not acute pediatric deficiency states.
Inadequate for emergencies: Life-threatening conditions like infantile beriberi with collapse, pulmonary hypertensive crisis, and severe lactic acidosis require immediate, proven interventions with standard thiamine 2, 3.
Practical Dosing Algorithm
For Suspected Acute Deficiency:
- Infantile beriberi with collapse: 25 mg IV cautiously 2
- Wernicke's encephalopathy: 100 mg IV initially, then 50-100 mg IM daily 2
- Severe lactic acidosis: Immediate IV thiamine administration (case reports show response within 12 hours) 4, 5
For Maintenance/Prevention:
- Preterm/term infants on PN: 0.35-0.50 mg/kg/day 1
- Children 1-18 years on PN: 1.2 mg/day 1
- Oral maintenance after acute treatment: 5-10 mg daily for one month 2
Monitoring Considerations:
- Age-related risk: Increasing age associated with poorer thiamine status in children with heart disease 6
- Dietary intake: Adequate dietary thiamine has protective effect (β=-0.37, P=0.003) 6
- Duration of PN: Risk increases with prolonged parenteral nutrition without adequate supplementation 5
Key Clinical Caveats
Warning about IV administration: "Wet" beriberi with myocardial failure must be treated as an emergency, with thiamine administered slowly by IV route 2. Repeated injections carry risks and should be done cautiously 2.
Prevention in at-risk patients: Children receiving IV dextrose with marginal thiamine status should receive 100 mg thiamine in the first few liters of IV fluid to prevent precipitating heart failure 2.
High index of suspicion required: Early identification prevents mortality and morbidity, particularly in the rarely described form with pulmonary hypertensive crisis 3.